| Literature DB >> 29739389 |
Michaela Mathes1, Christoph Maas2, Christine Bleeker2, Julia Vek2, Wolfgang Bernhard2, Andreas Peter3,4,5, Christian F Poets2, Axel R Franz2,6.
Abstract
BACKGROUND: Feeding breast milk is associated with reduced morbidity and mortality, as well as improved neurodevelopmental outcome but does not meet the high nutritional requirements of preterm infants. Both plasma and urinary urea concentrations represent amino acid oxidation and low concentrations may indicate insufficient protein supply. This study assesses the effect of different levels of enteral protein on plasma and urinary urea concentrations and determines if the urinary urea-creatinine ratio provides reliable information about the protein status of preterm infants.Entities:
Keywords: Enteral feeding; Infant, newborn; Infant, premature; Milk, human; Nutrition; Protein supply; Supplementation; Targeted fortification; Urea concentration; Very low birth weight infant
Mesh:
Substances:
Year: 2018 PMID: 29739389 PMCID: PMC5941684 DOI: 10.1186/s12887-018-1136-5
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Fig. 1Concept of the interaction of actual protein intake and growth on plasma and urinary urea concentrations
Ingredients of the multicomponent fortifiers
| 5 g BEBA FM 85 | 5 g Study fortifier 10.01.DE.INF | |
|---|---|---|
| 74 kJ / 18 kcal | 90 kJ / 22 kcal | |
| Protein | 1,0 g | 1,8 g |
| Total carbohydrates (including:) | 3,3 g | 1,8 g |
| lactose | 0 g | 0 g |
| maltodextrin | 3,2 g | 1,8 g |
| Other carbohydrates | 0,1 g | 0 g |
| Total lipids (incuding:) | 0,02 g | 0,87 g |
| docosahexaenic acid (DHA) | 0,0075 g | |
| arachidonic acid (AA) | 0,0006 g | |
| Sodium | 20 mg | 33 mg |
| Potassium | 42 mg | 83 mg |
| Chloride | 17 mg | 29 mg |
| Calcium | 75 mg | 94 mg |
| Phosphor | 45 mg | 56 mg |
| Magnesium | 2 mg | 5 mg |
| Iron | 1,3 mg | 0,94 mg |
| Copper | 0,04 mg | 0 mg |
| Zinc | 0,8 mg | 0 mg |
| Iodine | 15 μg | 19 μg |
| Selenium | 1,5 μg | 4,25 μg |
| Vitamin A | 0,15 mg | 0,5 mg |
| Vitamin D | 2,5 μg | 5 μg |
| Vitamin E | 2,0 mg | 5 mg |
| Vitamin K | 4,0 μg | 10 μg |
| Vitamin C | 10 mg | 25 mg |
| Vitamin B1 | 0,05 mg | 0,19 mg |
| Vitamin B2 | 0,10 mg | 0,25 mg |
| Vitamin B6 | 0,05 mg | 0,16 mg |
| Folic Acid | 40 μg | 50 μg |
| Vitamin B5 | 0,4 mg | 0,88 mg |
| Vitamin B12 | 0,1 μg | 0,25 μg |
| Biotin | 3 μg | 4 μg |
Comparison of the comorbidities of LPG and HPG
| LPG | HPG | ||
|---|---|---|---|
| NEC (≥ Bell stage 2A) | 0(0) | 0(0) | 1 |
| PDA therapy (indomethacin or ibuprofen) | 4(13) | 3(10) | 1 |
| BPD (physiological definitiona) | 0(0) | 2(7) | 0,49 |
| ROPb/c | 0(0) | 1(3) | 1 |
| IVHd | 3(10) | 0(0) | 0,24 |
| PVL / intra-parenchymal bleeding | 0(0) / 0(0) | 0(0) / 0(0) | 1 / 1 |
| Corticosteroid administration inhaled / systemice | 0(0) / 1(3) | 5(17) / 1(3) | 0,05 / 1 |
amoderate or severe BPD indicated by need for positive pressure respiratory support or supplemental oxygen at a postmenstrual age of 36 weeks to maintain an SpO2 > 90%, verified by a room air test where indicated
bno ophthalmologic examination in 6 patients
cmax. Stage of ROP in all participants: stage I
dmax. Grade of IVH in all participants: grade I
ebudesonide inhalation, systemic supply of hydrocortisone (no patient received dexamethasone)
Patient details lower-protein group vs. higher-protein group, data shown as number n (%), respectively median (p25-p75), or *mean (±SD)
| Lower-protein group | Higher-protein group | ||
|---|---|---|---|
| Sex female | 19(63) | 14(47) | 0,3 |
| Gestational age in weeks | 30,0(29,0–31,1) | 29,7(27,9–31,0) | 0,2 |
| Birth weight in g | 1215(1065–1393) | 1193(984–1326) | 0,61 |
| Day of randomisation | 7(6–7) | 7(6–8) | 0,75 |
| Length of hospital stay | 52(42–65) | 52(37–70) | 0,6 |
| Mean protein supply in g/kg/d (birth to end of intervention) | 3,82(3,59–3,93) | 4,30(4,11–4,43) | < 0,0001 |
| Mean energy supply in kcal/kg/d (birth to end of intervention) | 136(133–143) | 137(135–147) | 0,62 |
| Weight gain in g/kg/d (birth to end of intervention, primary outcome of the underlying study)* | 16,25 (±2,22)* | 16,02 (±2,48)* | 0,71 |
Fig. 2Protein intake 5 days before blood samples (BS) were taken a BS1: lower-protein group (4.02 (3.72–4.42)) vs. higher-protein group (4.69 (4.34–5.01)) p < 0.001; b BS2 - lower protein group (3.49 (3.30–3.99)) vs. higher-protein group (4.19 (3.92–4.38)) p < 0.0001
Fig. 3Plasma urea (PU) concentrations (mg/dl) – a Blood sample (BS) 1 lower-protein group 23.9 (17.7–29.6)) vs. higher-protein group 30.6 (22.8–37.6) p = 0.03; b BS2 lower-protein group 12.9 (11.4–16.3) vs. higher-protein group 19.2 (15.0–21.9) p = 0.0008
Urinary urea-creatinine-ratio in the lower protein group versus high protein group in week two to seven after birth, showing significant difference in week 3 and from week 5 to week 7
| Weeks | Lower-protein group | Higher-protein group | |
|---|---|---|---|
| 2 | 38,0 (24,1–52,7) | 43,3 (30,2–49,5) | 0.77 |
| 3 | 25,8 (16,9–41,1) | 39,9 (33,5–51,0) | 0.0019 |
| 4 | 26,2 (20,7–31,3) | 30,9 (24,4–46,5) | 0.086 |
| 5 | 21,0 (14,9–26,0) | 30,7 (26,2–38,5) | 0.0024 |
| 6 | 25,3 (17,4–29,6) | 33,7 (25,1–42,2) | 0.029 |
| 7 | 16,3 (12,1–30,8) | 34,0 (27,8–52,0) | 0.0083 |
Fig. 4Plasma urea concentration in mg/dl and Urinary urea-creatinine-ratio (UUCR) show highly significant positive correlation (p < 0.0001), ρ = 0.72; y = 11.28407 + 0.9221688*x
Fig. 5Actual protein intake (5d before blood sample (BS)) and a Plasma urea concentration (p < 0.0001; ρ = 0.59); y = − 25.8499 + 11.644884*x and b Urinary urea-creatinine ratio (UUCR) (p < 0.0001; ρ = 0.47) showed highly significant positive correlation; y = − 14.80586 + 11.401612*x